Publicacións nas que colabora con Andrés Jerez Cayuela (10)

2024

  1. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

    British Journal of Haematology

  2. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

2023

  1. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

    HemaSphere, Vol. 7, Núm. 10, pp. E961

2021

  1. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2018

  1. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia

    British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383

2017

  1. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621

2016

  1. Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes

    Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292

  2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes

    Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551

2013

  1. Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations

    British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86